SemBioSys touts its ApoA-I Milano product in wake of Pfizer deal
This article was originally published in Scrip
Executive Summary
SemBioSys Genetics claims that Pfizer's $420 million deal with The Medicines Company for the anti-atherosclerotic, ApoA-I Milano, is a boon for its own version of the compound.